Szintigraphische Diagnostik des Neuroblastoms mit meta-Jod-Benzylguanidin*

Abstract

In 1979/80 meta-iodobenzylguanidine (MIBG) was introduced as a radiopharmaceutical agent with high affinity to the adrenal medulla. It could be shown, that scintigraphic imaging with 131J labeled MIBG is a sensitive and highly specific method for localization of pheochromocytoma. In this connection we could demonstrate in 1983 that neuroblastoma can be visualized scintigraphically with MIBG as well. Until now 13 patients were examined with 131J-MIBG by our group: In 10 children with histologically proven neuroblastoma we found a specific enrichment in the tumor area. Besides the primary tumor local recurrence and metastases to bones, bone marrow and brain were detected. There was no neuroblastoma manifestation without MIBG uptake. In 3 patients with tumors other than neuroblastoma no uptake of MIBG was noticed. The results agree with those of other studies: If the physiological pattern of distribution is taken into consideration and if the proper imaging technique is adapted, 131J-MIBG scintigraphy is a highly sensitive and specific method for staging, monitoring of disease and follow-up of neuroblastoma.

Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: Results of the German neuroblastoma trial

“…Several years ago it was shown that mIBG was a useful substance for scintigraphic imaging of neuroblastoma [14,15]. On this experience together with laboratory data showing good in vitro uptake and killing of tumor cells in human neuroblastoma cell lines [ 161 the first treatment study [4] expanded.…”

Localization Procedures in Pheochromocytoma and Neuroblastoma

“…Thus l31I-MIBG uptake was observed in pheochromo cytoma [Shapiro et al, 1983;Fischer et al, 1982], neuroblastoma [Kimmig et al, 1983;Feine et al, 1984], métastasés of carcinoid tumors [Fischer et al, 1984] and in platelets [Feldman et al, 1984].…”

“…More recently, Kimmig et al [1983] reported the imaging of neuro blastoma and Fischer et al [1984] scintigra phy of métastasés of carcinoid tumors with the same radiopharmaceutical agent.…”

Verlaufskontrolle des Neuroblastoms Stadium IV: 123I-mIB G- Szintigraphie, Knochenszintigraphie und Katecholaminmetabolite

“…Das therapeutische Procedere ist vom exakten Staging und Therapiemonitoring abhängig. Dabei haben neben morphologisch orientierten bildgebenden Verfahren und der Bestimmung der Katecholaminmetabolite (Homovanillinsäure und Vanillinmandelsäure) in Serum und Urin (6) neben der Knochenszintigraphie seit der Einführung des Noradrenalin-Analogons Metaiodobenzylguanidin (mlBG, 21,22) nuklearmedizinischen Verfahren einen hohen Stellenwert (5,7,11).…”